Retinitis Pigmentosa
Disease Details
Family Health Simplified
- Description
- Retinitis Pigmentosa is a group of genetic disorders that cause progressive retinal degeneration and vision loss, often leading to blindness.
- Type
-
Retinitis pigmentosa is a group of inherited eye diseases that cause retinal degeneration. The types of genetic transmission for retinitis pigmentosa include:
1. Autosomal dominant
2. Autosomal recessive
3. X-linked recessive
Each type affects the likelihood and pattern of inheritance differently. - Signs And Symptoms
-
The initial retinal degenerative symptoms of retinitis pigmentosa are characterized by decreased night vision (nyctalopia) and the loss of the mid-peripheral visual field. The rod photoreceptor cells, which are responsible for low-light vision and are orientated mainly in the retinal periphery, are the retinal processes affected first during non-syndromic (without other conditions) forms of this disease. Visual decline progresses relatively quickly to the far peripheral field, eventually extending into the central visual field as tunnel vision increases. Visual acuity and color vision can become compromised due to accompanying loss of the cone photoreceptor cells, which are responsible for color vision, visual acuity, and sight in the central visual field. The progression of disease occurs in both eyes in a similar but not identical pattern.
A variety of indirect symptoms characterize retinitis pigmentosa along with the direct effects of the initial rod photoreceptor degeneration and later cone photoreceptor decline. Phenomena such as photophobia, which describes the event in which light is perceived as an intense glare, and photopsia, the presence of blinking, swirling or shimmering lights spontaneously occurring within the visual field, often manifest during the later stages of RP.
Findings related to RP have often been characterized in the fundus (back layer) of the eye as the "ophthalmic triad". This includes the development of (1) a mottled appearance of the retina and retinal pigment epithelium (RPE) that gives the same visual appearance of b
one spicule patterns (but are not bone spicules), (2) a waxy yellow appearance of the optic disk, and (3) the attenuation of blood vessels in size and Arterial/Venous ratio as they enter and exit the optic disk of the retina and transverse it.Non-syndromic RP (RP appears alone without other co-morbidities) usually presents a variety of the following symptoms:
Night blindness
Tunnel vision (due to loss of peripheral vision)
Latticework vision(due to patchy loss of peripheral vision)
loss of depth perception
Photopsia (Spontaneously occurring flashes/blinking/swirling/shimmering lights)
Photophobia (aversion to bright lights)
Development of the appearance of melanin pigment in a bone spicule pattern in the fundus (not bone tissue)
Slow adjustment from dark to light environments and vice versa
Blurring of vision
Poor color separation
Loss of central vision is the last to go, because this is a disease of the rods and not the cones which are the highest in number in the Central Vision (Macula and Fovea)
Eventual blindness (legally defined as 20 degrees or less in the best seeing eye or visual acuity of 20/200 or worse. The majority of patients do not become totally blind, often retaining limited or non-functional vision. - Prognosis
- The progressive nature of and lack of a definitive cure for retinitis pigmentosa contribute to the inevitably discouraging outlook for patients with this disease. While complete blindness is rare, the person's visual acuity and visual field will continue to decline as initial rod photoreceptor and later cone photoreceptor degradation proceeds.Studies indicate that children carrying the disease genotype benefit from presymptomatic counseling in order to prepare for the physical and social implications associated with progressive vision loss. While the psychological prognosis can be slightly alleviated with active counseling the physical implications and progression of the disease depend largely on the age of initial symptom manifestation and the rate of photoreceptor degradation, rather than access to prospective treatments. Corrective visual aids and personalized vision therapy provided by Low Vision Specialists may help patients correct slight disturbances in visual acuity and optimize their remaining visual field. Support groups, vision insurance, and lifestyle therapy are additional useful tools for those managing progressive visual decline.
- Onset
-
Onset: Retinitis pigmentosa (RP) typically begins with symptoms in childhood, adolescence, or early adulthood, though the exact age of onset can vary widely among individuals.
ASP.NET - Prevalence
- Retinitis pigmentosa (RP) has a prevalence of approximately 1 in 4,000 individuals worldwide.
- Epidemiology
-
Retinitis pigmentosa is the leading cause of inherited blindness, with approximately 1/4,000 individuals experiencing the non-syndromic form of their disease within their lifetime. It is estimated that 1.5 million people worldwide are currently affected. Early onset RP occurs within the first few years of life and is typically associated with syndromic disease forms, while late onset RP emerges from early to mid-adulthood.
Autosomal dominant and recessive forms of retinitis pigmentosa affect both male and female populations equally; however, the less frequent X-linked form of the disease affects male recipients of the X-linked mutation, while females usually remain unaffected carriers of the RP trait. The X-linked forms of the disease are considered severe, and typically lead to complete blindness during later stages. In rare occasions, a dominant form of the X-linked gene mutation will affect both males and females equally.Due to the genetic inheritance patterns of RP, many isolate populations exhibit higher disease frequencies or increased prevalence of a specific RP mutation. Pre-existing or emerging mutations that contribute to rod photoreceptor degeneration in retinitis pigmentosa are passed down through familial lines; thus, allowing certain RP cases to be concentrated to specific geographical regions with an ancestral history of the disease. Several hereditary studies have been performed to determine the varying prevalence rates in Maine (USA), Birmingham (England), Switzerland (affects 1/7000), Denmark (affects 1/2500), and Norway. Navajo Indians display an elevated rate of RP inheritance as well, which is estimated as affecting 1 in 1878 individuals. Despite the increased frequency of RP within specific familial lines, the disease is considered non-discriminatory and tends to equally affect all world populations. - Intractability
- Retinitis pigmentosa is generally considered intractable because there is no cure currently available. The progression of the disease leads to gradual and permanent vision loss. However, some treatments and interventions can help manage symptoms and slow progression. These include vitamin A supplementation, use of visual aids, and, in certain cases, retinal implants or gene therapy, though still largely experimental.
- Disease Severity
- Retinitis pigmentosa is a group of genetic disorders causing progressive retinal degeneration, primarily affecting the photoreceptor cells known as rods and cones. The severity of the disease can vary considerably among individuals. Some patients may experience night blindness and peripheral vision loss in adolescence, while others may maintain relatively good vision until adulthood. The progression of the disease typically spans several decades, eventually leading to significant visual impairment or blindness. Nanotechnology is emerging as a potential avenue for developing novel treatments, such as nano-based drug delivery systems and retinal implants, which may help slow disease progression or restore some vision. However, these applications remain largely experimental and are not yet widely available.
- Healthcare Professionals
- Disease Ontology ID - DOID:10584
- Pathophysiology
-
A variety of retinal molecular pathway defects have been matched to multiple known RP gene mutations. Mutations in the rhodopsin gene (RHO), which is responsible for the majority of autosomal-dominantly inherited RP cases, disrupts the rhodopsin protein essential for translating light into decipherable electrical signals within the phototransduction cascade of the central nervous system. Defects in the activity of this G-protein-coupled receptor are classified into distinct classes that depend on the specific folding abnormality and the resulting molecular pathway defects. The Class I mutant protein's activity is compromised as specific point mutations in the protein-coding amino acid sequence affect the pigment protein's transport to the outer segment of the eye, where the phototransduction cascade is localized. Additionally, the misfolding of Class II rhodopsin gene mutations disrupts the protein's conjunction with 11-cis-retinal to induce proper chromophore formation. Additional mutants in this pigment-encoding gene affect protein stability, disrupt mRNA integrity post-translationally, and affect the activation rates of transducin and opsin optical proteins.Additionally, animal models suggest that the retinal pigment epithelium fails to phagocytose the outer rod segment discs that have been shed, leading to an accumulation of outer rod segment debris. In mice that are homozygous recessive for retinal degeneration mutation, rod photoreceptors stop developing and undergo degeneration before cellular maturation completes. A defect in cGMP-phosphodiesterase has also been documented; this leads to toxic levels of cGMP.
Oxidative damage associated with lipid peroxidation is a potential cause of cone cell death in retinitis pigmentosa. - Carrier Status
-
Retinitis pigmentosa (RP) is an inherited retinal dystrophy characterized by progressive peripheral vision loss and night vision difficulties, leading to central vision loss. Carrier status for RP depends on the specific genetic mutation and inheritance pattern involved. RP can be inherited in an autosomal recessive, autosomal dominant, or X-linked manner.
1. **Autosomal Recessive RP**: Individuals must inherit two copies of the mutated gene (one from each parent) to manifest the disease. Carriers have one mutated gene and one normal gene and typically do not show symptoms.
2. **Autosomal Dominant RP**: Only one copy of the mutated gene is needed to develop the disease. Carriers who have one mutated gene will usually show symptoms.
3. **X-Linked RP**: The mutated gene is located on the X chromosome. Males with the mutation will usually show symptoms because they have only one X chromosome. Females can be carriers if they have one mutated X chromosome and one normal X chromosome; they may show mild symptoms or be asymptomatic.
Understanding the carrier status for a specific individual requires genetic testing and counseling. - Mechanism
-
Retinitis pigmentosa (RP) is a group of genetic disorders that lead to progressive retinal degeneration and vision loss. Here's a detailed look into its mechanisms and molecular aspects:
### Mechanism
In retinitis pigmentosa, there is a progressive loss of photoreceptors, initially affecting the rod cells responsible for peripheral and night vision, and subsequently the cone cells which are responsible for central and color vision. As the photoreceptor cells degenerate, pigmented clumps known as bone spicule formations accumulate in the retina.
### Molecular Mechanisms
1. **Genetic Mutations:** RP is primarily caused by mutations in numerous genes that are crucial for the normal function of photoreceptors and retinal pigment epithelium (RPE). These genes can be inherited in autosomal dominant, autosomal recessive, or X-linked manners.
2. **Rhodopsin Mutations:** Rhodopsin is a key photopigment in rod cells. Mutations in the rhodopsin gene (RHO) are a common cause of autosomal dominant RP. These mutations can lead to misfolded proteins that are toxic to cells, causing rod photoreceptor degeneration.
3. **Protein Misfolding and Trafficking Defects:** Mutations in genes involved in photoreceptor protein folding and trafficking, such as RHO and PRPF31, lead to the production of malfunctioning proteins, triggering photoreceptor cell death.
4. **Defective Retinal Metabolism:** Mutations in genes like PDE6A and PDE6B disrupt the phototransduction cascade, impairing the conversion of light signals into electrical signals, which is essential for vision. This eventually causes photoreceptor cell degeneration.
5. **Oxidative Stress:** Accumulation of oxidative stress and the inability to detoxify reactive oxygen species (ROS) contributes to the degeneration of the photoreceptors and RPE cells.
6. **Inflammation:** Chronic inflammation and immune responses within the retina can exacerbate photoreceptor cell death and retinal degeneration.
Understanding these molecular mechanisms is crucial for developing therapeutic strategies aimed at slowing down or halting the progression of retinitis pigmentosa. - Treatment
- There is currently no cure for retinitis pigmentosa, but the efficacy and safety of various prospective treatments are currently being evaluated. The efficiency of various supplements, such as vitamin A, DHA, NAC, and lutein, in delaying disease progression remains an unresolved, yet prospective treatment option. Clinical trials investigating optic prosthetic devices, gene therapy mechanisms, and retinal sheet transplantations are active areas of study in the partial restoration of vision in retinitis pigmentosa patients.
- Compassionate Use Treatment
-
Compassionate use treatment, off-label, and experimental treatments for retinitis pigmentosa (RP) include several emerging therapies and approaches:
1. **Gene Therapy**: Examples include voretigene neparvovec-rzyl (Luxturna), which is FDA-approved for mutations in the RPE65 gene. Other gene therapies are in clinical or experimental stages for different genetic mutations causing RP.
2. **Retinal Implants**: Devices like the Argus II Retinal Prosthesis System provide a form of artificial vision for select patients with severe RP.
3. **Stem Cell Therapy**: Experimental approaches involve using stem cells to replace or repair damaged retinal cells. These treatments are still largely in clinical trial phases.
4. **Pharmacological Treatments**: Drugs such as Valproic acid, N-acetylcysteine, and others are being investigated for their neuroprotective properties, although more research is needed to validate their efficacy.
5. **CRISPR and Gene Editing**: Experimental treatments using CRISPR technology aim to correct genetic mutations causing RP, though these are in early research stages.
6. **Nutritional Supplements**: High doses of vitamin A, omega-3 fatty acids (such as DHA), and other antioxidants are used off-label to potentially slow the progression of RP, based on varying levels of supportive evidence.
7. **Optogenetics**: This approach involves making remaining retinal cells light-sensitive and is being explored in experimental settings.
Each of these treatments varies in its stage of development and approval status, and their applicability may depend on the specific genetic cause and stage of the disease in the patient. - Lifestyle Recommendations
-
For Retinitis Pigmentosa, consider the following lifestyle recommendations:
1. **Regular Eye Examinations**: Periodic check-ups with an ophthalmologist to monitor the progression of the disease.
2. **Proper Lighting**: Use adequate lighting to reduce eye strain, especially in low-light conditions.
3. **Protective Eyewear**: Wear sunglasses with UV protection to shield your eyes from harmful UV rays.
4. **Healthy Diet**: Maintain a diet rich in vitamins and antioxidants, particularly vitamins A, C, and E, and omega-3 fatty acids to support overall eye health.
5. **Exercise**: Engage in regular physical activity to maintain overall health, which can indirectly benefit eye health.
6. **Assistive Devices**: Use magnifiers, screen readers, and other assistive technologies to aid in daily tasks.
7. **Avoid Smoking**: Smoking can worsen eye health; avoiding it is beneficial.
8. **Emotional Support**: Seek support from counselors or support groups to deal with the psychological impact of the disease.
These measures can help manage symptoms and improve quality of life, though they cannot halt disease progression. - Medication
-
There are currently no definitive medications to cure retinitis pigmentosa (RP). However, certain treatments can help manage symptoms or slow disease progression. Some approaches include:
1. **Vitamin A Palmitate:** High doses of this vitamin may slow the progression in some patients, but it should be taken under medical supervision due to potential toxicity.
2. **Omega-3 fatty acids:** Found in fish and supplements, these may also have a beneficial effect when combined with Vitamin A.
3. **Gene Therapy:** While still largely in the experimental stages, some gene therapies have shown promise in clinical trials for certain genetic types of RP.
4. **Retinal Implants:** Although not a medication, devices like the Argus II can sometimes help to restore a form of vision in those who have lost it due to RP.
Consulting with a healthcare specialist for personalized medical advice is important. - Repurposable Drugs
-
Repurposable drugs for retinitis pigmentosa (RP) include:
1. **N-acetylcysteine (NAC)** - An antioxidant that may help reduce oxidative stress in the retina.
2. **Vitamin A** - Supplements have been studied for their potential to slow the progression of RP, although high doses must be used with caution.
3. **Diltiazem** - A calcium channel blocker that has been explored for its neuroprotective properties in animal models.
4. **Metformin** - Commonly used for diabetes, this drug has been researched for its potential to enhance cellular function and survival in the retina.
Further studies are needed to confirm the efficacy and safety of these drugs in patients with retinitis pigmentosa. - Metabolites
- Retinitis pigmentosa is a group of genetic disorders that cause retinal degeneration. There is no widespread or definitive use of metabolites as treatment. Currently, research is ongoing in various areas including gene therapy, retinal implants, and pharmacological interventions, but the specific role of metabolites is not established in mainstream treatment or management plans.
- Nutraceuticals
-
Retinitis pigmentosa is a group of genetic disorders that affect the retina's ability to respond to light. There is limited evidence on the effectiveness of nutraceuticals (natural substances that provide health benefits) specifically for retinitis pigmentosa. Some research suggests that vitamins A, E, and omega-3 fatty acids, particularly DHA, might have some beneficial effects. However, it is crucial to consult with a healthcare provider before starting any supplementation.
As for nanotechnology (nan), its application in retinitis pigmentosa is still largely in the experimental stages. Researchers are exploring the use of nanoparticles for targeted drug delivery, gene therapy, and as carriers for neuroprotective agents, aiming to slow down retinal degeneration and potentially restore vision. Advances in this field are promising but still require further investigation and clinical trials. - Peptides
-
Retinitis pigmentosa (RP) is a group of genetic disorders that cause retinal degeneration. There have been several studies exploring the use of peptides and nanoparticles as potential therapeutic strategies:
1. **Peptides**: Peptides have been investigated for their neuroprotective properties in RP. For instance, certain peptides derived from growth factors or designed to mimic neurotrophic factors could potentially protect photoreceptors from degeneration.
2. **Nanoparticles**: Nanotechnology offers promising approaches for treating RP. Nanoparticles can be used to deliver drugs, genes, or peptides directly to the retina, enhancing the efficiency and specificity of the treatment. These nanoparticles can help bypass biological barriers and provide sustained release of therapeutic agents.
Research in these areas is ongoing, and while some results are promising, more studies are needed to establish the efficacy and safety of these treatments for RP.